-+ 0.00%
-+ 0.00%
-+ 0.00%

Oric initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPC

PUBT·05/04/2026 20:24:16
Listen to the news
Oric initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPC
  • Oric Pharmaceuticals selected 400 mg once-daily rinzimetostat with darolutamide as recommended Phase 3 dose for Himalayas-1, global registrational trial in post-abiraterone metastatic castration-resistant prostate cancer expected to start in 1H 2026.
  • Early results were already presented, supporting a differentiated safety profile and signs of disease control versus standard therapies, positioning program for late-stage development.
  • Another early dataset in patients previously treated with androgen receptor inhibitors was also presented, showing durability that could extend benefit from hormonal therapy in a setting where responses are typically short-lived.
  • Program update is expected in 2H 2026, with cash and investments of USD 419.7 million projected to fund operations into 2H 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-203993), on May 04, 2026, and is solely responsible for the information contained therein.